This product is a ING4 expressing oncolytic herpes simplex virus, which is based on HSV-1 with ICP27 deleted. ICP27 is highly cytotoxic probably due to its secondary role of preventing the splicing of pre-mRNAs in favour of translation from the mainly unspliced hepes RNAs. Deletion of ICP27 might produce a safer and less cytotoxic system when combined with other oncolytic-rendered modifications. This product can be used in oncolytic virotherapy research and further recombinant HSV construction.
Specifications
Family
Herpesviridae
Species
Herpes simplex virus
Serotype
Herpes simplex virus 1
Backbone
HSV-1 (ΔICP27)
Backbone Background
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as human herpesvirus 1 and 2 (HHV-1 and HHV-2), are two members of the human Herpesviridae family, a set of viruses that produce viral infections in the majority of humans. Modified Herpes simplex virus is considered as a potential therapy for cancer and has been extensively clinically tested to assess its oncolytic ability.
Gene Modification
ΔICP27
Promoter
SV40
Transgene
ING4
Type of Transgene
Cytokine
Related Target/Protein
Inhibitor of growth family member 4
Capsid Modification
None
Titer
>1*10^8 PFU
Related Diseases
Tumor
Transgene
Alternative Names
ING4, my036, p29ING4, inhibitor of growth family member 4
Inhibitor of growth protein 4 is a protein that in humans is encoded by the ING4 gene.
Customer Reviews and Q&As
There are currently no customer reviews or questions for ING4-expressing Oncolytic Herpes Simplex Virus 1 (ΔICP27), SV40-ING4 (CyOV-0216XY). Click the button below to contact us or submit your feedback about this product.
All products and services are for Research Use Only. Not For Clinical Use.